KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Free Cash Flow (2018 - 2025)

Esperion Therapeutics (ESPR) has disclosed Free Cash Flow for 8 consecutive years, with $45.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 230.08% year-over-year to $45.1 million, compared with a TTM value of -$13.3 million through Dec 2025, up 43.85%, and an annual FY2025 reading of -$13.3 million, up 43.85% over the prior year.
  • Free Cash Flow was $45.1 million for Q4 2025 at Esperion Therapeutics, up from -$4.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $53.8 million in Q1 2024 and bottomed at -$89.1 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$30.6 million, with a median of -$36.3 million recorded in 2023.
  • Peak annual rise in Free Cash Flow hit 230.08% in 2025, while the deepest fall reached 331.5% in 2025.
  • Year by year, Free Cash Flow stood at -$57.7 million in 2021, then rose by 26.4% to -$42.5 million in 2022, then grew by 12.75% to -$37.1 million in 2023, then grew by 6.53% to -$34.6 million in 2024, then surged by 230.08% to $45.1 million in 2025.
  • Business Quant data shows Free Cash Flow for ESPR at $45.1 million in Q4 2025, -$4.3 million in Q3 2025, and -$31.4 million in Q2 2025.